Obamacare Premiums Set to Double in 2026 as Subsidy Expiration Looms Amid U.S. Shutdown 
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy 
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines 
SK Hynix Considers U.S. ADR Listing to Boost Shareholder Value Amid Rising AI Chip Demand 
NASA Resumes Cygnus XL Cargo Docking with Space Station After Software Fix 
Asian Stocks Rally as Tech Rebounds, China Lags on Nvidia Competition Concerns 
BOJ Expected to Deliver December Rate Hike as Economists See Borrowing Costs Rising Through 2025 
SoftBank Shares Slide as Oracle’s AI Spending Plans Fuel Market Jitters 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
Asian Stocks Slide as Central Bank Decisions and Key Data Keep Investors Cautious 
Is space worth the cost? Accounting experts say its value can’t be found in spreadsheets 
Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options 
Neuralink Expands Brain Implant Trials with 12 Global Patients 
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission 
A team of Japanese scientists has developed a method that utilizes glucose and fragmented antibodies in reducing an abnormal accumulation of protein in the brains of mice with Alzheimer’s disease.
According to Takanori Yokota, a neurology professor at the university who was part of the team, they hope accomplishment will lead to the development of a new therapy that is safer and more efficient than its conventional antibody-used counterpart.
The amyloid beta protein accumulation in the brain is believed to trigger Alzheimer’s.
The researchers, primarily from Tokyo Medical and Dental University and the Innovation Center of Nanomedicine (iCONM), encapsulated fragments of an antibody that can attach itself to the protein and remove it from the brain into a so-called nanomachine.
They also attached glucose molecules to the nanomachine's surface, making it simpler for the brain to receive the antibody.
The mice with abnormally high levels of amyloid beta due to the disease were given injections of the encapsulated antibody fragments by the researchers. The agent was administered weekly for 10 weeks.
In contrast to just injecting them there, the study found that employing a nanomachine can deliver 80 times more antibody fragments to the brain.
It was also established that this technique can be used to get rid of amyloid beta lumps, which prevented the protein from gathering.
Because a whole antibody is too large to be placed in many places, the researchers chose to employ antibody fragments instead.
The result was a positive effect that was unanticipated.
Historically, the blood-brain barrier, which determines what to take in from blood vessels to protect the brain, prevented the entire prescribed medication to eliminate the protein from reaching the brain.
Therapeutic antibodies for Alzheimer's disease are well known for having undesirable side effects, such as inflamed brain swelling.
As the fragmented antibody lacks the portion that causes inflammatory reactions, the team anticipates that this side effect may be avoided.
